US20190120886A1 - Sensor arrangement for a packaging of a medicament - Google Patents
Sensor arrangement for a packaging of a medicament Download PDFInfo
- Publication number
- US20190120886A1 US20190120886A1 US16/228,128 US201816228128A US2019120886A1 US 20190120886 A1 US20190120886 A1 US 20190120886A1 US 201816228128 A US201816228128 A US 201816228128A US 2019120886 A1 US2019120886 A1 US 2019120886A1
- Authority
- US
- United States
- Prior art keywords
- layer
- sensor arrangement
- arrangement according
- layers
- exendin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000004806 packaging method and process Methods 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title description 40
- 230000001419 dependent effect Effects 0.000 claims abstract 2
- 239000000126 substance Substances 0.000 claims description 19
- 239000004065 semiconductor Substances 0.000 claims description 18
- 239000002019 doping agent Substances 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 238000005259 measurement Methods 0.000 claims description 8
- 238000005286 illumination Methods 0.000 claims description 7
- 239000011800 void material Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000004458 analytical method Methods 0.000 claims description 2
- 239000004020 conductor Substances 0.000 claims description 2
- 239000010410 layer Substances 0.000 description 156
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 238000009792 diffusion process Methods 0.000 description 43
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000009516 primary packaging Methods 0.000 description 7
- 238000009517 secondary packaging Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 5
- 230000001747 exhibiting effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000767 polyaniline Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- JBRZTFJDHDCESZ-UHFFFAOYSA-N AsGa Chemical compound [As]#[Ga] JBRZTFJDHDCESZ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229910015894 BeTe Inorganic materials 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 229910004613 CdTe Inorganic materials 0.000 description 1
- -1 Chinacridon Chemical compound 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229910002601 GaN Inorganic materials 0.000 description 1
- 229910005542 GaSb Inorganic materials 0.000 description 1
- 229910005543 GaSe Inorganic materials 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 229910001218 Gallium arsenide Inorganic materials 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 229910000673 Indium arsenide Inorganic materials 0.000 description 1
- GPXJNWSHGFTCBW-UHFFFAOYSA-N Indium phosphide Chemical compound [In]#P GPXJNWSHGFTCBW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910000577 Silicon-germanium Inorganic materials 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 229910007709 ZnTe Inorganic materials 0.000 description 1
- FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021417 amorphous silicon Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- UHYPYGJEEGLRJD-UHFFFAOYSA-N cadmium(2+);selenium(2-) Chemical compound [Se-2].[Cd+2] UHYPYGJEEGLRJD-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 229910021419 crystalline silicon Inorganic materials 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- WPYVAWXEWQSOGY-UHFFFAOYSA-N indium antimonide Chemical compound [Sb]#[In] WPYVAWXEWQSOGY-UHFFFAOYSA-N 0.000 description 1
- RPQDHPTXJYYUPQ-UHFFFAOYSA-N indium arsenide Chemical compound [In]#[As] RPQDHPTXJYYUPQ-UHFFFAOYSA-N 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000012811 non-conductive material Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- PJQYNUFEEZFYIS-UHFFFAOYSA-N perylene maroon Chemical compound C=12C3=CC=C(C(N(C)C4=O)=O)C2=C4C=CC=1C1=CC=C2C(=O)N(C)C(=O)C4=CC=C3C1=C42 PJQYNUFEEZFYIS-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- CLYVDMAATCIVBF-UHFFFAOYSA-N pigment red 224 Chemical compound C=12C3=CC=C(C(OC4=O)=O)C2=C4C=CC=1C1=CC=C2C(=O)OC(=O)C4=CC=C3C1=C42 CLYVDMAATCIVBF-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000123 polythiophene Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- IFLREYGFSNHWGE-UHFFFAOYSA-N tetracene Chemical compound C1=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C21 IFLREYGFSNHWGE-UHFFFAOYSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- TVIVIEFSHFOWTE-UHFFFAOYSA-K tri(quinolin-8-yloxy)alumane Chemical compound [Al+3].C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1.C1=CN=C2C([O-])=CC=CC2=C1 TVIVIEFSHFOWTE-UHFFFAOYSA-K 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R27/00—Arrangements for measuring resistance, reactance, impedance, or electric characteristics derived therefrom
- G01R27/02—Measuring real or complex resistance, reactance, impedance, or other two-pole characteristics derived therefrom, e.g. time constant
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01J—MEASUREMENT OF INTENSITY, VELOCITY, SPECTRAL CONTENT, POLARISATION, PHASE OR PULSE CHARACTERISTICS OF INFRARED, VISIBLE OR ULTRAVIOLET LIGHT; COLORIMETRY; RADIATION PYROMETRY
- G01J1/00—Photometry, e.g. photographic exposure meter
- G01J1/02—Details
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01K—MEASURING TEMPERATURE; MEASURING QUANTITY OF HEAT; THERMALLY-SENSITIVE ELEMENTS NOT OTHERWISE PROVIDED FOR
- G01K13/00—Thermometers specially adapted for specific purposes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01K—MEASURING TEMPERATURE; MEASURING QUANTITY OF HEAT; THERMALLY-SENSITIVE ELEMENTS NOT OTHERWISE PROVIDED FOR
- G01K3/00—Thermometers giving results other than momentary value of temperature
- G01K3/02—Thermometers giving results other than momentary value of temperature giving means values; giving integrated values
- G01K3/04—Thermometers giving results other than momentary value of temperature giving means values; giving integrated values in respect of time
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01K—MEASURING TEMPERATURE; MEASURING QUANTITY OF HEAT; THERMALLY-SENSITIVE ELEMENTS NOT OTHERWISE PROVIDED FOR
- G01K7/00—Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat ; Power supply therefor, e.g. using thermoelectric elements
- G01K7/01—Measuring temperature based on the use of electric or magnetic elements directly sensitive to heat ; Power supply therefor, e.g. using thermoelectric elements using semiconducting elements having PN junctions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N25/00—Investigating or analyzing materials by the use of thermal means
- G01N25/56—Investigating or analyzing materials by the use of thermal means by investigating moisture content
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/0004—Gaseous mixtures, e.g. polluted air
- G01N33/0009—General constructional details of gas analysers, e.g. portable test equipment
- G01N33/0027—General constructional details of gas analysers, e.g. portable test equipment concerning the detector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- H01L51/00—
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10K—ORGANIC ELECTRIC SOLID-STATE DEVICES
- H10K99/00—Subject matter not provided for in other groups of this subclass
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/02—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
- G01N27/04—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance
- G01N27/12—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluid; of a solid body in dependence upon reaction with a fluid, for detecting components in the fluid
- G01N27/121—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance by investigating resistance of a solid body in dependence upon absorption of a fluid; of a solid body in dependence upon reaction with a fluid, for detecting components in the fluid for determining moisture content, e.g. humidity, of the fluid
Definitions
- the present invention relates to the field of sensors and sensor arrangements to detect and to monitor at least one ambient parameter or ambient condition to which a medicament or a packaging of a medicament is exposed.
- the present invention relates to sensor arrangements to be integrated into a primary or secondary packaging of a medicament to monitor ambient parameters, such like temperature, exposure to light, humidity, or presence of particular substances, preferably gaseous substances, over a comparatively long time interval.
- Medicaments such as pharmaceutical products have to be kept and stored in a predefined way. Many medicaments require for instance constant refrigeration and must not be kept or stored above a predefined maximum temperature. Moreover, some medicaments are rather sensitive to bright illumination and should therefore be kept in a rather dark or dimmed environment. Other medicaments are rather sensitive to humidity and should be therefore not exposed to humidity.
- the medicament may be of further use even after passing of the best before date.
- respective amounts of medicaments will be discarded after a lapse of their best before date, simply as a precaution and irrespective of the actual constitution of the medicament.
- the medicament might be temporarily exposed to inadmissible ambient parameters and may therefore exhibit premature degradation even prior to its best before date. Since such degradation of a medicament may not be discernible by medical staff or end users, there exists a certain danger or hazard, that a prematurely degradated medicament is administered to a patient. Such administering may constitute a hazard to the health of the patient.
- the sensor arrangement should be able to provide qualitative and quantitative information about the actual status and constitution of the medicament.
- the sensor arrangement should be adapted to monitor physical and analytical parameters on the basis of negligible power consumption or even without power consumption.
- the first and the second layer at least in an initial configuration, comprise different concentrations of a diffusible component.
- the diffusible component i.e. its concentration in the first and/or in the second layer has a measurable impact on the conductivity of first and/or second layers.
- the diffusible component is sensitive to the at least one ambient parameter to be monitored with the present sensor arrangement. In other words, the diffusion process of the diffusible component is governed or at least influenced by the ambient parameter the sensor arrangement is exposed to.
- the sensor arrangement features a concentration gradient across the interface of first and second layers, which, depending on the magnitude, intensity and/or duration the sensor arrangement is exposed to the ambient parameter, levels out or mutually adjusts.
- concentration of the diffusible component is subject to modification due to detrimental ambient conditions.
- a modification of the concentration of the diffusible component in the first and/or in the second layer leads to a measurable modification of the electrical conductivity of respective layers, which can be readily measured and detected by means of a suitable measurement device.
- first and second layers itself does not require supply of electrical or mechanical energy. Hence, the sensor arrangement becomes subject to a measurable diffusion process even without energy consumption. Only determination of a resulting change of electrical conductivity of first and/or second layers may require application of respective electrical signals. Generally, the diffusion process to take place between first and second layers may be monitored during the entire life cycle of the medicament. Depending on the type of ambient parameter to be monitored with the sensor arrangement, the diffusion process may even be suitable to integrate the ambient parameter over time, thereby allowing to determine e.g. the total amount of thermal energy to which the sensor arrangement has been exposed to for a predefined time interval.
- the diffusion behaviour in particular the velocity of the diffusible component is affectable and/or controllable by the magnitude and/or intensity of the ambient parameter. Moreover, the diffusion behaviour and the progress of diffusion depends on the duration, the sensor arrangement is exposed to the respective ambient parameter.
- the sensor arrangement is generally adapted to provide qualitative and quantitative information about the progress of the diffusion process, which is an indicator on the magnitude, intensity and duration of exposure to the respective ambient condition.
- the diffusible component is either embedded in or is arranged at the first layer.
- the diffusible component initially present in or on the first layer is furthermore adapted to diffuse towards or to diffuse even into the second layer.
- First and second layers as well as the diffusible component are particularly designed with respect to each other to provide a well-defined and reproducible diffusion process at given ambient parameters.
- first and second layers comprise a crystalline structure, in which the diffusible component is embedded as impurity or defect.
- the diffusion process may exhibit an interstitial or substitutional mechanism, generally referred to as lattice diffusion.
- the sensor arrangement further comprises a third layer being at least partially in direct contact with a surface of the second layer that faces away from the first layer.
- the second layer is sandwiched between first and third layers, wherein the layers are arranged on top of each other and are further arranged in a parallel way.
- first, second and third layers form a stack of layers, wherein the various single layers comprise substantially identically-shaped contact surfaces.
- the third layer may comprise a similar or identical material compared to the first layer.
- the third layer may exhibit a similar or identical concentration of a diffusible component. It is also conceivable, that only the first layer comprises the diffusible component and that the third layer comprises a similar or identical but substantially undoped material.
- first layer and the third layer are electrically connectible to a measurement device in order to determine the conductivity of the second layer which is sandwiched therebetween.
- first and third layers may comprise or provide electrical contacts, preferably at a side facing away from the second layer. By means of these contacts, a conductivity of the second layer sandwiched between first and third layers can be conveniently measured with an appropriate measurement device, which is for instance adapted to determine the electrical conductivity or resistivity of the second layer.
- the ambient parameter to be monitored by the sensor arrangement is either the ambient temperature, an ambient illumination or radiation and/or ambient humidity.
- the diffusion processes dependence on thermal- or radiation energy which is deposited to the first, to the second and/or to the third layer is effectively exploited.
- the diffusion process may also be directly or indirectly governed by ambient humidity, which may be monitored accordingly.
- the sensor arrangement may be also applicable to measure presence and/or concentration of particular gaseous substances that are present in the vicinity of the sensor arrangement.
- the sensor arrangement may exhibit a particular sensitivity regarding selected spectral ranges of the electromagnetic spectrum.
- the sensor arrangement is able to detect electromagnetic radiation in the UV spectral range, in the visible as well as in the infrared spectral ranges.
- the diffusion process may be designed to become particularly sensitive to selected spectral ranges in particular to the visible and UV spectral range. This way, exposure to UV or visible light can be monitored.
- first and/or the third layer comprise a conducting or semiconducting material provided with a diffusible dopant substance.
- first and/or third layers are made of a semiconducting material in form of crystalline solids or in form of amorphous or liquid semiconductors. Suitable semiconductor materials are for instance crystalline silicon but also hydrogenated amorphous silicon as well as mixtures of arsenic, selenium and tellurium in a variety of proportions.
- Other available and generally suitable semiconductor materials may comprise a combination of chemical elements of the third and fifth main group, such like GaP, GaAs, InP, InSb, InAs, GaSb, GaN, AN, InN, Al x Gai_ x As, In x Gai_ x N and/or of the second and sixth main group, such like ZnO, TnS, ZnSe, ZnTe, CdS, CdSe, CdTe, Hg ( i_ x) Cd (x) Te, BeSe, BeTe, HgS.
- chemical elements of the third and fifth main group such like GaP, GaAs, InP, InSb, InAs, GaSb, GaN, AN, InN, Al x Gai_ x As, In x Gai_ x N and/or of the second and sixth main group, such like ZnO, TnS, ZnSe, ZnTe, CdS, CdSe, CdT
- the first and/or the third layer may also comprise a III-VI semiconductors, such like GaS, GaSe, GaTe, InS, InSe, InTe, I-III-VI semiconductors, such like CuInSe 2 , CuInGsSe 2 , CuInS 2 , CuInGaS 2 and/or IV-IV semiconducting materials, such like SiC or SiGe.
- III-VI semiconductors such like GaS, GaSe, GaTe, InS, InSe, InTe
- I-III-VI semiconductors such like CuInSe 2 , CuInGsSe 2 , CuInS 2 , CuInGaS 2 and/or IV-IV semiconducting materials, such like SiC or SiGe.
- the first and/or the third layer may also comprise organic semiconducting materials, such like Tetracen, Pentacen, Phthalocyanine, Polythiophene, PTCDA, MePTCDI, Chinacridon, Acridon, Indanthron, Flavanthron, Perinon, Alq3, Polyvinylcarbazol or TCNQ.
- organic semiconducting materials such like Tetracen, Pentacen, Phthalocyanine, Polythiophene, PTCDA, MePTCDI, Chinacridon, Acridon, Indanthron, Flavanthron, Perinon, Alq3, Polyvinylcarbazol or TCNQ.
- first and/or third layers can also be n-doped by embedding phosphor, arsenic or antimony into the semiconducting material.
- organic semiconducting materials selective carbon atoms in a chain structure of respective polymers could be substituted to provide intermediate energy levels in a respective energy band of such molecules.
- electrically conductive polymers such like Polyaniline (PANI) may form a basis to provide a humidity sensing arrangement, since such organic semiconducting materials typically exhibit a degradation when exposed to water and/or oxygen.
- the second layer typically sandwiched between the first and the third layer is substantially non-conductive in an initial configuration.
- the second layer features an increased conductivity when absorbing or receiving diffusible components from the first and/or from the third layer.
- the diffusible component or the dopant substance is initially embedded or provided in or at the first and/or in or at the third layer. This way, a concentration gradient between the first and the second layer and/or between the third and the second layer can be established which induces a respective diffusion process once the ambient parameter of relevance triggers or accelerates the diffusion process.
- the dopant substance comprises a molecular component exhibiting a chemical reaction when exposed to H 2 O.
- the dopant substance is adapted to chemically react with H 2 O and wherein at least one residual component of the dopant substance, e.g. molecular oxygen may exhibit a diffusion process with regard to the first, second and/or third layer, which leads to a measurable modification of the electrical conductivity of the second layer.
- the second layer comprises at least two opposite or opposing surface segments comprise contact surfaces of different sizes with the adjacently arranged first and third layers. It has turned out, that the diffusion process can be manipulated and even controlled by the size of the contact surface between first and second layer or between third and second layer, respectively. Generally, the magnitude of the measurable diffusion enlarges with an increasing contact surface. By way of suitable modifications of mutually abutting contact surfaces of respective layers, the general diffusion behaviour of the diffusible component can be modified and controlled, e.g. in order to shift the sensitivity of the sensor arrangement towards lower or larger values or ranges of the measurable ambient parameter.
- first and/or the third layer comprise at least two geometrical mutually non-overlapping structures lying in the plane of a respective layer and being separated by a filling material or by a void space. It is of particular benefit, when the first and/or the third layer comprise one or several, for instance triangular or rectangular shaped geometrical structures in order to provide particular surface segments of a respective layer featuring differently sized contact surface segments, each of which exhibiting a different sensitivity of diffusion regarding the respective ambient parameter.
- the various contact surface segments of the first and/or of the third layer are preferably separately coupled with a measurement device in order to the determine their electrical conductivity and the degree of diffusion individually.
- the surface segment of first and/or third layers may be arranged in a two-dimensional grid, which may be of regular or irregular type.
- At least one geometrical structure of the first layer traverses at least one geometrical structure of the third layer in a projection parallel to a surface normal of the first and/or of the third layer.
- the geometrical structures as well as the layers in which these structures are embedded in are not in direct contact with each other but are separated by the initially insulating second layer.
- first and third layer at least partially overlap, numerous overlapping regions of different size can be provided, each of which exhibiting a different degree of sensitivity regarding the ambient parameter to be monitored.
- the sensor arrangement can be used to continuously monitor said ambient parameter can be extended.
- the first layer and the third layer of the sensor arrangement comprise a substantially identical geometric shape.
- the first layer is rotated by a predefined angle with respect to the third layer with respect to a rotation axis extending substantially parallel to the surface normal (z) of first and/or third layer.
- the angle of rotation of first and third layer may be governed by the specific geometric shape of the geometric structure of respective layers. In case the layers comprise several parallel oriented triangular-shaped geometric structures, the layers may for instance be rotated by about 90 degree.
- the rotation axis may be located in the centre of the surface of first and/or third layer, such that the lateral extension of layers and/or the stack of layers remains substantially unaffected by said mutual rotation.
- the layers are of substantially quadratic shape.
- the geometrical structures of the first layer and the third layer form a pattern comprising at least two surface segments of different size.
- the pattern may comprise a particular symmetry featuring at least two surface segments of equal size. This way, a certain redundancy can be provided.
- the measurable conductivity of the second layer in regions of overlapping surface segments of substantially equal size can be generally used to determine an average value, thereby allowing to increase the precision and reliability of the sensor arrangement.
- the sensor arrangement further comprises an electric antenna circuit and/or a processing unit.
- the antenna circuit, the processing unit and the stack of layers may be integrated into a single chip, which itself may be integrated into or attached to a primary or secondary packaging of a medicament.
- the antenna and/or the processing unit may be designed as components to wirelessly communicate with further analysis devices, such like RFID readers or the like.
- the entire sensor arrangement may be integrated into an RFID chip assembly, which may extract required electrical energy for the determination of the electrical conductivity of the second layer from an externally applied RF field.
- the invention reflects in a packaging to accommodate or to receive and/or to store at least one item therein and further comprises at least one sensor arrangement as described above.
- the packaging may be designed for storage of food or beverages as well as for medicaments.
- the packaging is designed to keep and/or to store items and substances that can become subject to degeneration or deterioration.
- the packaging comprises a secondary or primary packaging for a medicament.
- the primary packaging may comprise a vitreous body being at least partially filled with a liquid medicament.
- the primary packaging may comprise a bottle, an ampoule, a carpule, a cartridge or a syringe.
- the secondary packaging may comprise an injection device being equipped with the primary packaging, e.g. in form of a cartridge filled with the medicament.
- the secondary packaging may also comprise a casing to receive a plurality of medicaments or respective medical devices.
- the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary
- the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- GLP-1 glucagon-like peptide
- exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(w-carboxy
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Goserelin.
- a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
- An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins ( ⁇ 150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
- the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- Ig immunoglobulin
- the Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two 0 sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- Ig heavy chain There are five types of mammalian Ig heavy chain denoted by a, 6, 8, y, and u.
- the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; a and y contain approximately 450 amino acids and 6 approximately 500 amino acids, while u and 8 have approximately 550 amino acids.
- Each heavy chain has two regions, the constant region (C H ) and the variable region (V H ).
- the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
- Heavy chains y, a and 6 have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains IA and 8 have a constant region composed of four immunoglobulin domains.
- the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
- the variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
- CL constant domain
- VL variable domain
- the approximate length of a light chain is 211 to 217 amino acids.
- Each antibody contains two light chains that are always identical; only one type of light chain, lc or k, is present per antibody in mammals.
- variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
- VL variable light
- VH variable heavy chain
- CDRs Complementarity Determining Regions
- an “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
- Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
- the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
- F(ab′)2 is divalent for antigen binding.
- the disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′.
- the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HCl or HBr salts.
- Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
- solvates are for example hydrates.
- FIG. 1 schematically illustrates a cross section of the sensor arrangement in an initial configuration
- FIG. 2 is indicative of the sensor arrangement after or during exposure to ambient conditions
- FIG. 3 shows another sensor arrangement with a first layer having a reduced contact surface
- FIG. 4 shows a sensor arrangement with an increased first layer
- FIG. 5 shows a triangular-shaped geometrical structure of the first and/or the third layer
- FIG. 6 schematically illustrates a crossed configuration of first and third layers, each of which having a several triangular-shaped geometric structures
- FIG. 7 schematically illustrates the sensor arrangement equipped with an antenna and a processing unit.
- the sensor arrangement as schematically shown in cross section in FIGS. 1 to 4 comprises a stack 26 of three substantially overlapping layers 12 , 14 , 16 .
- a first layer 12 comprises numerous diffusible components 22 embedded therein, which under exposure to a particular ambient parameter 24 start to diffuse into the adjacent second layer 14 ′, as indicated in FIG. 2 .
- the second layer 14 ′ may exhibit a modified electrical inductivity compared to the second layer 14 as shown in FIG. 1 in its initial configuration. This modification in conductivity is generally measurable by a respective measurement device 18 being in electrical contact with the first layer 12 and with the third layer 16 via contacts 20 .
- the outer layers may comprise a semiconducting material and may be n- or p-doped by the diffusible dopant substance 22 .
- the diffusion process which may be influenced by temperature, by intensity of radiation illumination or by humidity 24 may stop or at least slow down when an equilibrium of the concentration of the diffusible component 22 establishes in the first layer 12 ′ and in the second layer 14 ′.
- the concentration of the diffusible component 22 as well as the semiconducting materials of first and third layers 12 , 16 have to be chosen appropriately.
- the material and diffusible component may be chosen and arranged in such a way, that the diffusion process starts or accelerates when a threshold of a respective ambient parameter 24 is traversed, for instance, when the ambient temperature rises above or drops below a predetermined temperature 24 .
- the diffusion process will not be measurable, even after a comparatively long period of time. But as soon as the ambient temperature 24 traverses the predefined threshold, the diffusion process will at least slowly start. As the temperature 24 further rises, e.g. above a second predefined temperature, the diffusion process may accelerate accordingly until an equilibrium configuration is reached. Depending on the degree of diffusion, the conductivity of the second layer to be measured with the measurement device 18 may become subject to respective measurable changes. Since the general diffusion behaviour of the diffusible component is known and/or scaled, the measurable degree of diffusion can give sufficient information about the time and/or the intensity the sensor arrangement 10 has been exposed to the ambient parameter.
- the second layer 14 comprises a substantially non-conductive material
- its conductivity may rise and its electrical resistivity may decrease the more diffusible particles 22 penetrate the interface between first layer 12 and second layer 14 .
- the diffusion behaviour may be particularly designed and adapted to the chemical or physical degradation properties of the respective medicament. Hence, the actual and inevitable degradation process of the medicament may be mapped and imaged by the sensor arrangement.
- FIGS. 3 and 4 demonstrate the influence of the size of adjacent layers 12 ′′, 14 on the magnitude of the diffusion process.
- the second layer 14 comprises surface 30 being substantially identical in size to the layer's lower surface or lower surface 32 .
- only a surface segment 34 of the upper surface 30 is in direct contact with the first layer 12 ′′. Therefore, the degree and magnitude of the diffusion process as well as the total number of diffusible particles 22 diffusing towards and into the second layer 14 from the size-reduced first layer 12 ′′ is reduced compared to the embodiment as illustrated in FIG. 4 , where respective contact surfaces of the first layer 12 and the second layer 14 are substantially identical.
- the first layer 12 can be initially provided with the same or with another diffusible component 22 which is adapted to diffuse towards the second layer 14 .
- the lower contact surface 36 of the second layer 14 is almost identical to and completely overlaps with a corresponding upper contact surface of the third layer 16 .
- FIG. 5 is illustrative of a particular geometrical structure 40 having a triangular shape and featuring a rather wide end section 42 to the left and a rather small and tipped end section 44 at its opposite end illustrated to the right in FIG. 5 .
- the first layer 12 may comprise four adjacently disposed and identically shaped geometrical structures 40 , 50 , 60 , 70 having a respective void space 45 , 55 , 65 therebetween.
- the third layer 16 comprises a comparable or substantially identical geometrical structure.
- the third layer 16 comprises four geometrical structures 40 , 50 , 60 , 70 , each of which featuring a triangular shape and being adjacently arranged in the plane of the layer.
- the two layers 12 , 16 of substantially identical shape are mutually rotated by about 90° in order to generate a pattern 46 of surface segments, of which a few segments 4040 , 4050 , 4060 , 4070 , 5040 , 6050 , 7040 , 7060 are exemplary indicated in the FIG. 6 .
- the geometrical structures 40 , 50 , 60 , 70 of first and third layers 12 , 16 substantially overlap in a projection along a surface normal (z) of first and/or third layer 12 , 16 .
- the pattern 46 as shown in FIG. 6 in which substantially overlapping surface segments 40 , 50 , 60 , 70 of first and third layers 12 , 16 mutually overlap are indicated as black areas.
- the second layer 14 comprises a patterned structure that generally corresponds to the pattern of overlapping surface segments 4040 , 4050 , 4060 , 4070 , 5040 , 6050 , 7040 , 7060 , . . . as shown in FIG. 6 .
- the measurable range of the sensor arrangement as well as the time period, the sensor is capable to monitor a diffusion process can be extended.
- the surface segment 4070 may exhibit a larger diffusion susceptibility compared to a rather small surface segment 7040 .
- the surface segment 7040 may reach an equilibrium configuration and hence a maximum conductivity when exposed to about 30° C. for more than 24 hours.
- the surface segment 4070 may exhibit a comparable conductivity only after an exposure to at least 36° C. for more than 7 days.
- the residual surface segments may each provide a sensitivity between these two extreme samples.
- the sensor arrangement 10 featuring a multiplicity of surface segments of different size may cover a rather large temperature range and a rather large time interval including several months or even years. It is of particular benefit, that some diffusion processes are rather inactive below a predefined threshold temperature but may increase in an exponential way as soon as the temperature rises above such a threshold.
- the embodiment as depicted in FIG. 6 features a multiplicity of surface segments having of substantially equal size due to the 90° rotation of the first layer 12 with respect to the third layer 16 .
- the two surface segments 5040 and 7060 are of substantially equal size.
- the surface segments 5040 and 7060 When exposed to the ambient parameter or ambient condition, the surface segments 5040 and 7060 typically exhibit an identical or at least highly similar diffusion behaviour. This way, a kind of a two-fold redundancy can be provided and/or the measurable conductivity of the two interrelated surface segments 5040 , 7060 can be used to determine an average value.
- the present sensor arrangement 10 is not only applicable to determine and to monitor a temperature history, to which the sensor arrangement 10 has been exposed to.
- the sensor arrangement 10 can be used as a humidity sensor by making use of a molecular component as the dopant substance 22 which exhibits a chemical reaction when exposed to H 2 O. Then, a residual component of a chemical reaction and/or a reaction product may diffuse into the second layer 14 after the sensor arrangement 10 has been exposed to humidity.
- at least one of first or third layers should be in contact with the ambient atmosphere.
- the sensor arrangement may be also suitable to detect the chemical constitution in the ambient environment.
- the sensor arrangement may also be applicable as a gas sensor, wherein at least one of the layers 12 , 14 , 16 is susceptible to receive and/or to embed a gaseous substance being present in the ambient atmosphere. For instance, molecular oxygen or other gases may diffuse into and through the first layer 12 towards the second layer 14 as soon as the sensor arrangement is exposed to an ambient atmosphere.
- FIG. 7 finally shows the sensor arrangement 10 further comprising an antenna circuit 28 and a processing unit 38 .
- the antenna circuit 28 is particularly adapted to receive and/or to transmit a power signal, from which electrical power can be derived to determine the conductivity of the second layer 14 of the stack 26 of layers 12 , 14 , 16 .
- the entire sensor arrangement 10 may be designed as a passive RFID tag which does not require an on-site power source but which is only activated when disposed in the broadcasting area of an RFID reading arrangement.
- the sensor arrangement 10 does not require an own power source since the diffusion process between the layers 12 , 14 , 16 is only governed and controlled by the ambient conditions that are to be monitored and measured.
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Combustion & Propulsion (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Wrappers (AREA)
- Packages (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Laminated Bodies (AREA)
Abstract
The present disclosure relates to a sensor arrangement to monitor at least one ambient parameter, the sensor arrangement may comprise a first layer having a first electrical conductivity, and a second layer having a second electrical conductivity different than the first electrical conductivity, wherein a portion of the second layer is in direct contact with the first layer, and wherein the first layer and the second layer, in an initial configuration, comprise different concentrations of a diffusible component such that the electrical conductivity of the second layer is dependent on the concentration of the diffusible component within the second layer.
Description
- The present application is a continuation of U.S. patent application Ser. No. 14/367,828, filed Jun. 20, 2014, which is a U.S. National Phase Application pursuant to 35 U.S.C. § 371 of International Application No. PCT/EP2012/076318 filed Dec. 20, 2012, which claims priority to European Patent Application No. 11195529.0 filed Dec. 23, 2011. The entire disclosure contents of these applications are herewith incorporated by reference in the present application.
- The present invention relates to the field of sensors and sensor arrangements to detect and to monitor at least one ambient parameter or ambient condition to which a medicament or a packaging of a medicament is exposed. In particular, the present invention relates to sensor arrangements to be integrated into a primary or secondary packaging of a medicament to monitor ambient parameters, such like temperature, exposure to light, humidity, or presence of particular substances, preferably gaseous substances, over a comparatively long time interval.
- Medicaments, such as pharmaceutical products have to be kept and stored in a predefined way. Many medicaments require for instance constant refrigeration and must not be kept or stored above a predefined maximum temperature. Moreover, some medicaments are rather sensitive to bright illumination and should therefore be kept in a rather dark or dimmed environment. Other medicaments are rather sensitive to humidity and should be therefore not exposed to humidity.
- Depending on their exposure to ambient parameters, such like temperature, illumination and humidity, particular medicaments may become subject to an irreversible degradation process. It is therefore of importance to label such medicaments with a best before date, after which the medicament should no longer be used and applied. The best before date is typically provided on a secondary or primary packaging of the medicament. The best before date has to be determined in such a way, that the medicament can still be used at the given date given that it has been transported and stored appropriately. The best before date, prior to which the medicament should be used is calculated and determined on the basis of the general degradation properties of said medicament and its time of production.
- However, if a medicament which is sensitive to heat and illumination is always kept in a dimmed and/or refrigerated environment, the medicament may be of further use even after passing of the best before date. However, since it is generally not possible or impractical to non-destructively test the medicament, respective amounts of medicaments will be discarded after a lapse of their best before date, simply as a precaution and irrespective of the actual constitution of the medicament.
- In another scenario, the medicament might be temporarily exposed to inadmissible ambient parameters and may therefore exhibit premature degradation even prior to its best before date. Since such degradation of a medicament may not be discernible by medical staff or end users, there exists a certain danger or hazard, that a prematurely degradated medicament is administered to a patient. Such administering may constitute a hazard to the health of the patient.
- In the rare event, a particular medicament turns out to constitute a health risk, as a precaution, those medicaments that where produced in the same batch have to be traced and have to be discarded for safety reasons. Hence, up to now there exists no sufficient and reliable monitoring system to determine the actual state and usability of individual medicaments in a non-destructive way.
- It is therefore an object of the present invention to provide a simple and cost-efficient sensor arrangement allowing to monitor ambient parameters to which a medicament and/or its first or secondary packaging has been exposed to. The sensor arrangement should be able to provide qualitative and quantitative information about the actual status and constitution of the medicament. Moreover, the sensor arrangement should be adapted to monitor physical and analytical parameters on the basis of negligible power consumption or even without power consumption.
- The present invention provides a sensor arrangement to monitor at least one ambient parameter to which the sensor arrangement is exposed to. The sensor arrangement comprises a first layer exhibiting a first electrical conductivity and further comprises at least a second layer exhibiting a second electrical conductivity. First and second electrical conductivities are different in magnitude and the first and second layers are at least partially in direct mechanical contact with each other. Preferably, first and second layers comprise an even and flat shaped geometry and are arranged in a mutual contact configuration, in which upper and/or lower planar surfaces of first and second layers at least partially mutually abut.
- Additionally, the first and the second layer, at least in an initial configuration, comprise different concentrations of a diffusible component. The diffusible component, i.e. its concentration in the first and/or in the second layer has a measurable impact on the conductivity of first and/or second layers. Additionally, the diffusible component is sensitive to the at least one ambient parameter to be monitored with the present sensor arrangement. In other words, the diffusion process of the diffusible component is governed or at least influenced by the ambient parameter the sensor arrangement is exposed to.
- Regarding the diffusible component, the sensor arrangement features a concentration gradient across the interface of first and second layers, which, depending on the magnitude, intensity and/or duration the sensor arrangement is exposed to the ambient parameter, levels out or mutually adjusts. In effect, the concentration of the diffusible component is subject to modification due to detrimental ambient conditions. A modification of the concentration of the diffusible component in the first and/or in the second layer leads to a measurable modification of the electrical conductivity of respective layers, which can be readily measured and detected by means of a suitable measurement device.
- The diffusion process taking place between first and second layers itself does not require supply of electrical or mechanical energy. Hence, the sensor arrangement becomes subject to a measurable diffusion process even without energy consumption. Only determination of a resulting change of electrical conductivity of first and/or second layers may require application of respective electrical signals. Generally, the diffusion process to take place between first and second layers may be monitored during the entire life cycle of the medicament. Depending on the type of ambient parameter to be monitored with the sensor arrangement, the diffusion process may even be suitable to integrate the ambient parameter over time, thereby allowing to determine e.g. the total amount of thermal energy to which the sensor arrangement has been exposed to for a predefined time interval.
- In a preferred embodiment, the diffusion behaviour, in particular the velocity of the diffusible component is affectable and/or controllable by the magnitude and/or intensity of the ambient parameter. Moreover, the diffusion behaviour and the progress of diffusion depends on the duration, the sensor arrangement is exposed to the respective ambient parameter.
- This way, the sensor arrangement is generally adapted to provide qualitative and quantitative information about the progress of the diffusion process, which is an indicator on the magnitude, intensity and duration of exposure to the respective ambient condition.
- According to another preferred embodiment, the diffusible component is either embedded in or is arranged at the first layer. The diffusible component initially present in or on the first layer is furthermore adapted to diffuse towards or to diffuse even into the second layer. First and second layers as well as the diffusible component are particularly designed with respect to each other to provide a well-defined and reproducible diffusion process at given ambient parameters. Preferably, first and second layers comprise a crystalline structure, in which the diffusible component is embedded as impurity or defect. Hence, the diffusion process may exhibit an interstitial or substitutional mechanism, generally referred to as lattice diffusion.
- According to another preferred embodiment the sensor arrangement further comprises a third layer being at least partially in direct contact with a surface of the second layer that faces away from the first layer. Preferably, the second layer is sandwiched between first and third layers, wherein the layers are arranged on top of each other and are further arranged in a parallel way. Preferably, first, second and third layers form a stack of layers, wherein the various single layers comprise substantially identically-shaped contact surfaces. The third layer may comprise a similar or identical material compared to the first layer. Moreover, compared to the first layer, also the third layer may exhibit a similar or identical concentration of a diffusible component. It is also conceivable, that only the first layer comprises the diffusible component and that the third layer comprises a similar or identical but substantially undoped material.
- In still another preferred embodiment, the first layer and the third layer are electrically connectible to a measurement device in order to determine the conductivity of the second layer which is sandwiched therebetween. In such a configuration, first and third layers may comprise or provide electrical contacts, preferably at a side facing away from the second layer. By means of these contacts, a conductivity of the second layer sandwiched between first and third layers can be conveniently measured with an appropriate measurement device, which is for instance adapted to determine the electrical conductivity or resistivity of the second layer.
- In still another aspect, the ambient parameter to be monitored by the sensor arrangement is either the ambient temperature, an ambient illumination or radiation and/or ambient humidity. In case the sensor arrangement is adapted to measure temperature and/or illumination, the diffusion processes dependence on thermal- or radiation energy which is deposited to the first, to the second and/or to the third layer is effectively exploited. Depending on the choice of materials for the first, second and/or third layers and/or depending on the choice of the diffusible component, the diffusion process may also be directly or indirectly governed by ambient humidity, which may be monitored accordingly. Accordingly, the sensor arrangement may be also applicable to measure presence and/or concentration of particular gaseous substances that are present in the vicinity of the sensor arrangement.
- The sensor arrangement may exhibit a particular sensitivity regarding selected spectral ranges of the electromagnetic spectrum. Typically, the sensor arrangement is able to detect electromagnetic radiation in the UV spectral range, in the visible as well as in the infrared spectral ranges. Moreover, the diffusion process may be designed to become particularly sensitive to selected spectral ranges in particular to the visible and UV spectral range. This way, exposure to UV or visible light can be monitored.
- In a further preferred aspect, the first and/or the third layer comprise a conducting or semiconducting material provided with a diffusible dopant substance. Preferably, first and/or third layers are made of a semiconducting material in form of crystalline solids or in form of amorphous or liquid semiconductors. Suitable semiconductor materials are for instance crystalline silicon but also hydrogenated amorphous silicon as well as mixtures of arsenic, selenium and tellurium in a variety of proportions. Other available and generally suitable semiconductor materials may comprise a combination of chemical elements of the third and fifth main group, such like GaP, GaAs, InP, InSb, InAs, GaSb, GaN, AN, InN, AlxGai_
x As, InxGai_x N and/or of the second and sixth main group, such like ZnO, TnS, ZnSe, ZnTe, CdS, CdSe, CdTe, Hg(i_x) Cd(x)Te, BeSe, BeTe, HgS. Moreover, the first and/or the third layer may also comprise a III-VI semiconductors, such like GaS, GaSe, GaTe, InS, InSe, InTe, I-III-VI semiconductors, such like CuInSe2, CuInGsSe2, CuInS2, CuInGaS2 and/or IV-IV semiconducting materials, such like SiC or SiGe. - Additionally or alternatively, the first and/or the third layer may also comprise organic semiconducting materials, such like Tetracen, Pentacen, Phthalocyanine, Polythiophene, PTCDA, MePTCDI, Chinacridon, Acridon, Indanthron, Flavanthron, Perinon, Alq3, Polyvinylcarbazol or TCNQ.
- Depending on the semiconducting material selected for the first and/or for the third layer, the choice of a diffusible dopant substance may vary. For instance, with silicon or germanium, elements of the third main group, such like boron, indium, aluminum or gallium may provide a p-doped semiconducting layer. Alternatively, first and/or third layers can also be n-doped by embedding phosphor, arsenic or antimony into the semiconducting material.
- With organic semiconducting materials, selective carbon atoms in a chain structure of respective polymers could be substituted to provide intermediate energy levels in a respective energy band of such molecules. In particular, electrically conductive polymers, such like Polyaniline (PANI) may form a basis to provide a humidity sensing arrangement, since such organic semiconducting materials typically exhibit a degradation when exposed to water and/or oxygen.
- In a further preferred embodiment, the second layer typically sandwiched between the first and the third layer is substantially non-conductive in an initial configuration. The second layer features an increased conductivity when absorbing or receiving diffusible components from the first and/or from the third layer.
- Additionally, it is of particular benefit, when the diffusible component or the dopant substance is initially embedded or provided in or at the first and/or in or at the third layer. This way, a concentration gradient between the first and the second layer and/or between the third and the second layer can be established which induces a respective diffusion process once the ambient parameter of relevance triggers or accelerates the diffusion process.
- In a further preferred embodiment, the dopant substance comprises a molecular component exhibiting a chemical reaction when exposed to H2O. This way, an effective humidity sensing configuration can be provided, wherein the dopant substance is adapted to chemically react with H2O and wherein at least one residual component of the dopant substance, e.g. molecular oxygen may exhibit a diffusion process with regard to the first, second and/or third layer, which leads to a measurable modification of the electrical conductivity of the second layer.
- In a further preferred embodiment, the second layer comprises at least two opposite or opposing surface segments comprise contact surfaces of different sizes with the adjacently arranged first and third layers. It has turned out, that the diffusion process can be manipulated and even controlled by the size of the contact surface between first and second layer or between third and second layer, respectively. Generally, the magnitude of the measurable diffusion enlarges with an increasing contact surface. By way of suitable modifications of mutually abutting contact surfaces of respective layers, the general diffusion behaviour of the diffusible component can be modified and controlled, e.g. in order to shift the sensitivity of the sensor arrangement towards lower or larger values or ranges of the measurable ambient parameter.
- It is of further benefit, when according to another embodiment the first and/or the third layer comprise at least two geometrical mutually non-overlapping structures lying in the plane of a respective layer and being separated by a filling material or by a void space. It is of particular benefit, when the first and/or the third layer comprise one or several, for instance triangular or rectangular shaped geometrical structures in order to provide particular surface segments of a respective layer featuring differently sized contact surface segments, each of which exhibiting a different sensitivity of diffusion regarding the respective ambient parameter.
- It is further of advantage when the conductivity of the second layer disposed between electrically insulated first and third layers is measured on the basis said surface segments. For determining the electrical conductivity of the second layer, the various contact surface segments of the first and/or of the third layer are preferably separately coupled with a measurement device in order to the determine their electrical conductivity and the degree of diffusion individually.
- The surface segment of first and/or third layers may be arranged in a two-dimensional grid, which may be of regular or irregular type.
- Here, it is further of advantage, when at least one geometrical structure of the first layer traverses at least one geometrical structure of the third layer in a projection parallel to a surface normal of the first and/or of the third layer. The geometrical structures as well as the layers in which these structures are embedded in are not in direct contact with each other but are separated by the initially insulating second layer.
- However, since the geometrical structures of first and third layer at least partially overlap, numerous overlapping regions of different size can be provided, each of which exhibiting a different degree of sensitivity regarding the ambient parameter to be monitored. In this way, the measurable range of the ambient parameter as well as the time interval, the sensor arrangement can be used to continuously monitor said ambient parameter can be extended.
- Moreover, it is also conceivable, that different geometrical structures of the first layer or of the third layer exhibit a different concentration of a diffusible component. Moreover, it is conceivable, that various geometrical structures of a common layer comprise different semiconducting materials doped with different diffusible dopants. Also in this way, the measurable range of the sensor arrangement may be extended.
- In a further preferred embodiment, the first layer and the third layer of the sensor arrangement comprise a substantially identical geometric shape. Moreover, the first layer is rotated by a predefined angle with respect to the third layer with respect to a rotation axis extending substantially parallel to the surface normal (z) of first and/or third layer. The angle of rotation of first and third layer may be governed by the specific geometric shape of the geometric structure of respective layers. In case the layers comprise several parallel oriented triangular-shaped geometric structures, the layers may for instance be rotated by about 90 degree.
- Typically, the rotation axis may be located in the centre of the surface of first and/or third layer, such that the lateral extension of layers and/or the stack of layers remains substantially unaffected by said mutual rotation. In this context it may be of particular benefit, when the layers are of substantially quadratic shape.
- According to another embodiment, it may be of further advantage when the geometrical structures of the first layer and the third layer form a pattern comprising at least two surface segments of different size. Moreover, especially in a rotated configuration, e.g. a 90° rotated constellation, the pattern may comprise a particular symmetry featuring at least two surface segments of equal size. This way, a certain redundancy can be provided. Also, the measurable conductivity of the second layer in regions of overlapping surface segments of substantially equal size can be generally used to determine an average value, thereby allowing to increase the precision and reliability of the sensor arrangement.
- In still another preferred embodiment, the sensor arrangement further comprises an electric antenna circuit and/or a processing unit. The antenna circuit, the processing unit and the stack of layers may be integrated into a single chip, which itself may be integrated into or attached to a primary or secondary packaging of a medicament. For instance, the antenna and/or the processing unit may be designed as components to wirelessly communicate with further analysis devices, such like RFID readers or the like.
- Moreover, if the antenna circuit is for instance designed to receive and/or to transmit RF signals, the entire sensor arrangement may be integrated into an RFID chip assembly, which may extract required electrical energy for the determination of the electrical conductivity of the second layer from an externally applied RF field.
- Additionally, the invention reflects in a packaging to accommodate or to receive and/or to store at least one item therein and further comprises at least one sensor arrangement as described above. The packaging may be designed for storage of food or beverages as well as for medicaments. In general, the packaging is designed to keep and/or to store items and substances that can become subject to degeneration or deterioration. In particular, the packaging comprises a secondary or primary packaging for a medicament. For instance, the primary packaging may comprise a vitreous body being at least partially filled with a liquid medicament. For instance, the primary packaging may comprise a bottle, an ampoule, a carpule, a cartridge or a syringe. Additionally, the secondary packaging may comprise an injection device being equipped with the primary packaging, e.g. in form of a cartridge filled with the medicament. Alternatively or additionally, the secondary packaging may also comprise a casing to receive a plurality of medicaments or respective medical devices.
- The term “drug” or “medicament”, as used herein, means a pharmaceutical formulation containing at least one pharmaceutically active compound,
- wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a protein, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound,
- wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy,
- wherein in a further embodiment the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30 human insulin; B29-N—(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N—(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-(w-carboxyheptadecanoyl)-des(B30) human insulin and B29-N-(w-carboxyheptadecanoyl) human insulin.
- Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- H-(Lys)4-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
- H-(Lys)5-des Pro36, des Pro37 Exendin-4(1-39)-NH2,
- des Pro36 Exendin-4(1-39),
- des Pro36 [Asp28] Exendin-4(1-39),
- des Pro36 [IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(0)14, Asp28] Exendin-4(1-39),
- des Pro36 [Met(0)14, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39),
- des Pro36 [Trp(02)25, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(0)14 Trp(02)25, Asp28] Exendin-4(1-39),
- des Pro36 [Met(0)14 Trp(02)25, IsoAsp28] Exendin-4(1-39); or
- des Pro36 [Asp28] Exendin-4(1-39),
- des Pro36 [IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(0)14, Asp28] Exendin-4(1-39),
- des Pro36 [Met(0)14, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39),
- des Pro36 [Trp(02)25, IsoAsp28] Exendin-4(1-39),
- des Pro36 [Met(0)14 Trp(02)25, Asp28] Exendin-4(1-39),
- des Pro36 [Met(0)14 Trp(02)25, IsoAsp28] Exendin-4(1-39),
- wherein the group -Lys6-NH2 may be bound to the C-terminus of the Exendin-4 derivative;
- or an Exendin-4 derivative of the sequence
- des Pro36 Exendin-4(1-39)-Lys6-NH2 (AVE0010),
- H-(Lys)6-des Pro36 [Asp28] Exendin-4(1-39)-Lys6-NH2,
- des Asp28 Pro36, Pro37, Pro38Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro38 [Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36 [Trp(02)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
- H-des Asp28 Pro36, Pro37, Pro38 [Trp(02)25] Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36 [Met(0)14, Asp28] Exendin-4(1-39)-Lys6-NH2,
- des Met(0)14 Asp28 Pro36, Pro37, Pro38 Exendin-4(1-39)-NH2,
- H-(Lys)6-desPro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-Lys6-des Pro36 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-Lys6-NH2,
- H-des Asp28 Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25] Exendin-4(1-39)-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Asp28] Exendin-4(1-39)-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-NH2,
- des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2,
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(S1-39)-(Lys)6-NH2,
- H-Asn-(Glu)5-des Pro36, Pro37, Pro38 [Met(0)14, Trp(02)25, Asp28] Exendin-4(1-39)-(Lys)6-NH2;
- or a pharmaceutically acceptable salt or solvate of any one of the afore-mentioned Exendin-4 derivative.
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008,
Chapter 50, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin. - A polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof. An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
- Antibodies are globular plasma proteins (−150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins. The basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- The Ig monomer is a “Y”-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two 0 sheets create a “sandwich” shape, held together by interactions between conserved cysteines and other charged amino acids.
- There are five types of mammalian Ig heavy chain denoted by a, 6, 8, y, and u. The type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; a and y contain approximately 450 amino acids and 6 approximately 500 amino acids, while u and 8 have approximately 550 amino acids. Each heavy chain has two regions, the constant region (CH) and the variable region (VH). In one species, the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes. Heavy chains y, a and 6 have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains IA and 8 have a constant region composed of four immunoglobulin domains. The variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone. The variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
- In mammals, there are two types of immunoglobulin light chain denoted by X and K. A light chain has two successive domains: one constant domain (CL) and one variable domain (VL). The approximate length of a light chain is 211 to 217 amino acids. Each antibody contains two light chains that are always identical; only one type of light chain, lc or k, is present per antibody in mammals.
- Although the general structure of all antibodies is very similar, the unique property of a given antibody is determined by the variable (V) regions, as detailed above. More specifically, variable loops, three each the light (VL) and three on the heavy (VH) chain, are responsible for binding to the antigen, i.e. for its antigen specificity. These loops are referred to as the Complementarity Determining Regions (CDRs). Because CDRs from both VH and VL domains contribute to the antigen-binding site, it is the combination of the heavy and the light chains, and not either alone, that determines the final antigen specificity.
- An “antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from. Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab). The third fragment, similar in size but containing the carboxyl terminal half of both heavy chains with their interchain disulfide bond, is the crystalizable fragment (Fc). The Fc contains carbohydrates, complement-binding, and FcR-binding sites. Limited pepsin digestion yields a single F(ab′)2 fragment containing both Fab pieces and the hinge region, including the H—H interchain disulfide bond. F(ab′)2 is divalent for antigen binding. The disulfide bond of F(ab′)2 may be cleaved in order to obtain Fab′. Moreover, the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group. Further examples of pharmaceutically acceptable salts are described in “Remington's Pharmaceutical Sciences” 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopedia of Pharmaceutical Technology.
- Pharmaceutically acceptable solvates are for example hydrates.
- It will be further apparent to those skilled in the pertinent art that various modifications and variations can be made to the present invention without departing from the spirit and scope of the invention. Further, it is to be noted, that any reference signs used in the appended claims are not to be construed as limiting the scope of the present invention.
- In the following, preferred embodiments of the invention will be described in greater detail by making reference to the drawings, in which:
-
FIG. 1 schematically illustrates a cross section of the sensor arrangement in an initial configuration, -
FIG. 2 is indicative of the sensor arrangement after or during exposure to ambient conditions, -
FIG. 3 shows another sensor arrangement with a first layer having a reduced contact surface and -
FIG. 4 shows a sensor arrangement with an increased first layer, -
FIG. 5 shows a triangular-shaped geometrical structure of the first and/or the third layer and -
FIG. 6 schematically illustrates a crossed configuration of first and third layers, each of which having a several triangular-shaped geometric structures, and -
FIG. 7 schematically illustrates the sensor arrangement equipped with an antenna and a processing unit. - The sensor arrangement as schematically shown in cross section in
FIGS. 1 to 4 comprises astack 26 of three substantially overlapping 12, 14, 16. Here, alayers first layer 12 comprises numerousdiffusible components 22 embedded therein, which under exposure to a particularambient parameter 24 start to diffuse into the adjacentsecond layer 14′, as indicated inFIG. 2 . As a consequence of this diffusion process, thesecond layer 14′ may exhibit a modified electrical inductivity compared to thesecond layer 14 as shown inFIG. 1 in its initial configuration. This modification in conductivity is generally measurable by arespective measurement device 18 being in electrical contact with thefirst layer 12 and with thethird layer 16 viacontacts 20. - The outer layers, hence
first layer 12 andthird layer 16, may comprise a semiconducting material and may be n- or p-doped by thediffusible dopant substance 22. The diffusion process, which may be influenced by temperature, by intensity of radiation illumination or byhumidity 24 may stop or at least slow down when an equilibrium of the concentration of thediffusible component 22 establishes in thefirst layer 12′ and in thesecond layer 14′. - In order to monitor and to measure the magnitude and duration of the
ambient parameter 24, the concentration of thediffusible component 22 as well as the semiconducting materials of first and 12, 16 have to be chosen appropriately. Depending on the type of medicament to which thethird layers present sensor arrangement 10 is to be attached to, the material and diffusible component may be chosen and arranged in such a way, that the diffusion process starts or accelerates when a threshold of a respectiveambient parameter 24 is traversed, for instance, when the ambient temperature rises above or drops below apredetermined temperature 24. - As long as the sensor arrangement is kept and stored below or above a predefined temperature, hence, within a predefined temperature range, the diffusion process will not be measurable, even after a comparatively long period of time. But as soon as the
ambient temperature 24 traverses the predefined threshold, the diffusion process will at least slowly start. As thetemperature 24 further rises, e.g. above a second predefined temperature, the diffusion process may accelerate accordingly until an equilibrium configuration is reached. Depending on the degree of diffusion, the conductivity of the second layer to be measured with themeasurement device 18 may become subject to respective measurable changes. Since the general diffusion behaviour of the diffusible component is known and/or scaled, the measurable degree of diffusion can give sufficient information about the time and/or the intensity thesensor arrangement 10 has been exposed to the ambient parameter. - In case that the
second layer 14 comprises a substantially non-conductive material, its conductivity may rise and its electrical resistivity may decrease the morediffusible particles 22 penetrate the interface betweenfirst layer 12 andsecond layer 14. The diffusion behaviour may be particularly designed and adapted to the chemical or physical degradation properties of the respective medicament. Hence, the actual and inevitable degradation process of the medicament may be mapped and imaged by the sensor arrangement. - The illustrations of
FIGS. 3 and 4 demonstrate the influence of the size ofadjacent layers 12″, 14 on the magnitude of the diffusion process. Here, thesecond layer 14 comprisessurface 30 being substantially identical in size to the layer's lower surface or lower surface 32. However, only asurface segment 34 of theupper surface 30 is in direct contact with thefirst layer 12″. Therefore, the degree and magnitude of the diffusion process as well as the total number ofdiffusible particles 22 diffusing towards and into thesecond layer 14 from the size-reducedfirst layer 12″ is reduced compared to the embodiment as illustrated inFIG. 4 , where respective contact surfaces of thefirst layer 12 and thesecond layer 14 are substantially identical. - Even though not particularly illustrated it is also conceivable, that not only the
first layer 12 but also thethird layer 16 can be initially provided with the same or with anotherdiffusible component 22 which is adapted to diffuse towards thesecond layer 14. In the sketch ofFIG. 3 , the lower contact surface 36 of thesecond layer 14 is almost identical to and completely overlaps with a corresponding upper contact surface of thethird layer 16. - Another way of spatially modifying the degree of diffusion across the interfaces between adjacently
12, 14, 16 is indicated indisposed layers FIGS. 5 and 6 .FIG. 5 is illustrative of a particulargeometrical structure 40 having a triangular shape and featuring a ratherwide end section 42 to the left and a rather small and tippedend section 44 at its opposite end illustrated to the right inFIG. 5 . As further shown inFIG. 6 , thefirst layer 12 may comprise four adjacently disposed and identically shaped 40, 50, 60, 70 having ageometrical structures 45, 55, 65 therebetween. Instead of a void space it is also conceivable to fill the planar gap between adjacently arrangedrespective void space 40, 50, 60, 70 with a different, substantially inert material. As further shown ingeometrical structures FIG. 6 , thethird layer 16 comprises a comparable or substantially identical geometrical structure. Hence, also thethird layer 16 comprises four 40, 50, 60, 70, each of which featuring a triangular shape and being adjacently arranged in the plane of the layer.geometrical structures - As further shown in
FIG. 6 , the two 12, 16 of substantially identical shape are mutually rotated by about 90° in order to generate alayers pattern 46 of surface segments, of which a 4040, 4050, 4060, 4070, 5040, 6050, 7040, 7060 are exemplary indicated in thefew segments FIG. 6 . Here, the 40, 50, 60, 70 of first andgeometrical structures 12, 16 substantially overlap in a projection along a surface normal (z) of first and/orthird layers 12, 16. Thethird layer pattern 46 as shown inFIG. 6 , in which substantially overlapping 40, 50, 60, 70 of first andsurface segments 12, 16 mutually overlap are indicated as black areas.third layers - Due to the triangular
40, 50, 60, 70 the sizes of thesegeometrical structures 4040, 4050, 4060, 4070, . . . mutually vary. In effect, and due to their different size, thesurface segments 4070 and 7040 for instance exhibit a different general diffusion behaviour, which leads to different local modifications of the electrical conductivity of thesurface segments second layer 14 disposed therebetween. It may be of further benefit here, when also thesecond layer 14 comprises a patterned structure that generally corresponds to the pattern of overlapping 4040, 4050, 4060, 4070, 5040, 6050, 7040, 7060, . . . as shown insurface segments FIG. 6 . In this way, the measurable range of the sensor arrangement as well as the time period, the sensor is capable to monitor a diffusion process can be extended. - When the
sensor arrangement 10 as shown inFIG. 6 is designed as a temperature monitoring arrangement, thesurface segment 4070 may exhibit a larger diffusion susceptibility compared to a rathersmall surface segment 7040. As a consequence and as a non-limiting example, thesurface segment 7040 may reach an equilibrium configuration and hence a maximum conductivity when exposed to about 30° C. for more than 24 hours. In comparison to that, thesurface segment 4070 may exhibit a comparable conductivity only after an exposure to at least 36° C. for more than 7 days. - The residual surface segments may each provide a sensitivity between these two extreme samples. In effect, the
sensor arrangement 10 featuring a multiplicity of surface segments of different size may cover a rather large temperature range and a rather large time interval including several months or even years. It is of particular benefit, that some diffusion processes are rather inactive below a predefined threshold temperature but may increase in an exponential way as soon as the temperature rises above such a threshold. - In this context it is to be noted that a comparable diffusion behaviour may be also observed when exposing the sensor arrangement in a brightly illuminated or in a rather humid environment, or when exposing the sensor arrangement in the vicinity of particular gaseous substances, which are themselves adapted to penetrate and to diffuse into the any one of the
12, 14, 16.layers - Moreover, the embodiment as depicted in
FIG. 6 features a multiplicity of surface segments having of substantially equal size due to the 90° rotation of thefirst layer 12 with respect to thethird layer 16. For instance, the two 5040 and 7060 are of substantially equal size. When exposed to the ambient parameter or ambient condition, thesurface segments 5040 and 7060 typically exhibit an identical or at least highly similar diffusion behaviour. This way, a kind of a two-fold redundancy can be provided and/or the measurable conductivity of the twosurface segments 5040, 7060 can be used to determine an average value.interrelated surface segments - As already indicated, the
present sensor arrangement 10 is not only applicable to determine and to monitor a temperature history, to which thesensor arrangement 10 has been exposed to. Moreover, thesensor arrangement 10 can be used as a humidity sensor by making use of a molecular component as thedopant substance 22 which exhibits a chemical reaction when exposed to H2O. Then, a residual component of a chemical reaction and/or a reaction product may diffuse into thesecond layer 14 after thesensor arrangement 10 has been exposed to humidity. For this purpose, at least one of first or third layers should be in contact with the ambient atmosphere. - Additionally, the sensor arrangement may be also suitable to detect the chemical constitution in the ambient environment. Hence, the sensor arrangement may also be applicable as a gas sensor, wherein at least one of the
12, 14, 16 is susceptible to receive and/or to embed a gaseous substance being present in the ambient atmosphere. For instance, molecular oxygen or other gases may diffuse into and through thelayers first layer 12 towards thesecond layer 14 as soon as the sensor arrangement is exposed to an ambient atmosphere. -
FIG. 7 finally shows thesensor arrangement 10 further comprising anantenna circuit 28 and aprocessing unit 38. Theantenna circuit 28 is particularly adapted to receive and/or to transmit a power signal, from which electrical power can be derived to determine the conductivity of thesecond layer 14 of thestack 26 of 12, 14, 16. Hence, thelayers entire sensor arrangement 10 may be designed as a passive RFID tag which does not require an on-site power source but which is only activated when disposed in the broadcasting area of an RFID reading arrangement. - Generally, the
sensor arrangement 10 does not require an own power source since the diffusion process between the 12, 14, 16 is only governed and controlled by the ambient conditions that are to be monitored and measured.layers
Claims (19)
1. A sensor arrangement to monitor at least one ambient parameter, the sensor arrangement comprising:
at least one of an electric antenna circuit or a processing unit;
a first layer having a first electrical conductivity and having a first initial concentration of a diffusible component when in an initial configuration; and
a second layer having a second initial concentration of the diffusible component different than the first initial concentration of the diffusible component in the first layer when in an initial configuration and having a second electrical conductivity different than the first electrical conductivity, the second electrical conductivity dependent on a current concentration of the diffusible component in the second layer, and at least a portion of the second layer being in direct contact with the first layer.
2. The sensor arrangement according to claim 1 , wherein the electric antenna circuit is configured to communicate wirelessly with at least one analysis device.
3. The sensor arrangement according to claim 1 , wherein the electric antenna circuit is configured to receive and/or to transmit RF signals.
4. The sensor arrangement according to claim 1 , comprising a stack of layers including the first layer and the second layer, wherein the processing unit and the stack of layers are integrated into a single chip.
5. The sensor arrangement according to claim 4 , wherein the processing unit, the electric antenna circuit, and the stack of layers are integrated into the single chip.
6. The sensor arrangement according to claim 1 , wherein the electric antenna circuit or processing unit, the first layer, and the second layer of the sensor arrangement are integrated into an RFID chip assembly.
7. The sensor arrangement according to claim 6 , wherein the RFID chip assembly is configured to extract electrical energy from an externally applied RF field for measurement of the second electrical conductivity of the second layer.
8. The sensor arrangement according to claim 6 , wherein the RFID chip assembly is void of an electric power source.
9. The sensor arrangement according to claim 1 , further comprising a third layer, at least a portion of the third layer being in direct contact with a surface of the second layer that faces away from the first layer.
10. The sensor arrangement according to claim 9 , wherein the first layer and the third layer are electrically connectable to a measurement device to measure the conductivity of the second layer sandwiched between the first layer and the third layer.
11. The sensor arrangement according to claim 1 , wherein the at least one ambient parameter is one or more of an ambient temperature, an ambient illumination, an ambient humidity, or a concentration of an ambient gaseous substance.
12. The sensor arrangement according to claim 1 , wherein the first layer, the third layer, or both comprise a conducting or semiconducting material provided with a diffusible dopant substance.
13. The sensor arrangement according to claim 9 , wherein the first layer, the third layer, or both comprise an organic semiconductor.
14. The sensor arrangement according to claim 12 , wherein the diffusible dopant substance comprises a molecular component that exhibits a chemical reaction when exposed to H2O.
15. The sensor arrangement according to claim 9 , wherein the second layer comprises:
a first surface having a first surface segment including a first contact portion in direct contact with the first layer; and
a second surface facing away from the first surface, the second surface having a second surface segment including a second contact portion in direct contact with the third layer, the second surface segment having a same area, shape, and orientation as the first surface segment and arranged opposite the first surface segment, the second contact portion having a different area than the third contact portion.
16. The sensor arrangement according to claim 9 , wherein each of the first layer and the third layer comprises a plurality of geometrical non-overlapping structures lying in the plane of the respective layer and being separated by a filling material or by a void space.
17. The sensor arrangement according to claim 16 , wherein at least one of the plurality of geometrical non-overlapping structures of the first layer traverses at least one of the plurality of geometrical non-overlapping structures of the third layer in a projection parallel to a surface normal of the first layer or the third layer.
18. The sensor arrangement according to claim 16 , wherein the plurality of geometrical non-overlapping structures of the first layer has substantially identical geometric shapes and a substantially identical arrangement of the shapes as those of the plurality of geometrically non-overlapping structures of the third layer with the arrangement of the shapes of the plurality of geometrical non-overlapping structures of the first layer being rotated with respect to the arrangement of the plurality of geometrical non-overlapping structures of the third layer by a predefined angle about a rotation axis extending substantially parallel to a surface normal of the first layer or the third layer.
19. A packaging for at least one item, comprising at least one sensor arrangement according to claim 1 .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/228,128 US20190120886A1 (en) | 2011-12-23 | 2018-12-20 | Sensor arrangement for a packaging of a medicament |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11195529 | 2011-12-23 | ||
| EP11195529.0 | 2011-12-23 | ||
| PCT/EP2012/076318 WO2013092823A1 (en) | 2011-12-23 | 2012-12-20 | Sensor arrangement for a packaging of a medicament |
| US201414367828A | 2014-06-20 | 2014-06-20 | |
| US16/228,128 US20190120886A1 (en) | 2011-12-23 | 2018-12-20 | Sensor arrangement for a packaging of a medicament |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/367,828 Continuation US10215786B2 (en) | 2011-12-23 | 2012-12-20 | Sensor arrangement for a packaging of a medicament |
| PCT/EP2012/076318 Continuation WO2013092823A1 (en) | 2011-12-23 | 2012-12-20 | Sensor arrangement for a packaging of a medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20190120886A1 true US20190120886A1 (en) | 2019-04-25 |
Family
ID=47520071
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/367,828 Expired - Fee Related US10215786B2 (en) | 2011-12-23 | 2012-12-20 | Sensor arrangement for a packaging of a medicament |
| US16/228,128 Abandoned US20190120886A1 (en) | 2011-12-23 | 2018-12-20 | Sensor arrangement for a packaging of a medicament |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/367,828 Expired - Fee Related US10215786B2 (en) | 2011-12-23 | 2012-12-20 | Sensor arrangement for a packaging of a medicament |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10215786B2 (en) |
| EP (1) | EP2795303A1 (en) |
| JP (2) | JP6262663B2 (en) |
| KR (1) | KR20140107430A (en) |
| CN (2) | CN108332881A (en) |
| AR (1) | AR089357A1 (en) |
| AU (1) | AU2012357007B2 (en) |
| BR (1) | BR112014014498A2 (en) |
| HK (1) | HK1198555A1 (en) |
| IL (1) | IL232691A0 (en) |
| IN (1) | IN2014CN04012A (en) |
| MX (1) | MX337266B (en) |
| RU (1) | RU2615795C2 (en) |
| TW (1) | TWI599772B (en) |
| WO (1) | WO2013092823A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3254093T3 (en) * | 2015-02-03 | 2020-08-17 | Boehringer Ingelheim Int | METHOD AND DEVICE FOR DETERMINING WATER CONTENT |
| KR101706251B1 (en) * | 2015-11-09 | 2017-02-14 | 부산대학교 산학협력단 | Apparatus and method for measuring thermal conductivity |
| KR102172350B1 (en) | 2016-04-19 | 2020-11-02 | 아날로그 디바이시즈 글로벌 언리미티드 컴퍼니 | Wear monitor device |
| US11024525B2 (en) * | 2017-06-12 | 2021-06-01 | Analog Devices International Unlimited Company | Diffusion temperature shock monitor |
| CN108246104B (en) * | 2017-12-30 | 2023-07-21 | 利穗科技(苏州)有限公司 | Digital ultrafiltration system and method |
| US20220323695A1 (en) * | 2019-09-25 | 2022-10-13 | Janssen Pharmaceuticals, Inc. | Drug delivery systems and methods |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198851A (en) | 1978-05-22 | 1980-04-22 | University Of Utah | Method and structure for detecting the concentration of oxygen in a substance |
| JPS58152042A (en) | 1982-03-04 | 1983-09-09 | Kureha Chem Ind Co Ltd | Molded article of polyacetylene |
| JPS62212560A (en) | 1986-03-13 | 1987-09-18 | Matsushita Electric Works Ltd | Preparation of gas sensor |
| US4892834A (en) * | 1986-08-07 | 1990-01-09 | Eic Laboratories, Inc. | Chemical sensor |
| JPH0810203B2 (en) | 1987-03-27 | 1996-01-31 | 朝安 中野 | Gas detection method |
| SU1762210A1 (en) | 1989-12-28 | 1992-09-15 | Научно-исследовательский институт "Дельта" | Gas sensor |
| US5501744A (en) | 1992-01-13 | 1996-03-26 | Photon Energy, Inc. | Photovoltaic cell having a p-type polycrystalline layer with large crystals |
| CN2158578Y (en) | 1992-12-29 | 1994-03-09 | 中国科学院长春光学精密机械研究所 | Large view-field photo-sensitive receiver |
| RU2097755C1 (en) * | 1995-04-25 | 1997-11-27 | Институт геохимии и аналитической химии им.В.И.Вернадского РАН | Ion-selective field-effect transistor |
| DE19548060A1 (en) | 1995-12-21 | 1997-06-26 | Siemens Ag | Power semiconductor device with temperature sensor that can be controlled by field effect |
| JP3368758B2 (en) * | 1996-07-16 | 2003-01-20 | 株式会社豊田中央研究所 | Thermal history detection method and thermal history detection sensor |
| US6077712A (en) | 1997-12-03 | 2000-06-20 | Trw Inc. | Semiconductor chemical sensor |
| TW429497B (en) * | 1999-03-02 | 2001-04-11 | United Microelectronics Corp | Method of monitoring in-line temperature |
| SE524102C2 (en) * | 1999-06-04 | 2004-06-29 | Appliedsensor Sweden Ab | Micro-hotplate device with integrated gas-sensitive field effect sensor |
| JP4377004B2 (en) | 1999-08-26 | 2009-12-02 | ゼネラル・エレクトリック・カンパニイ | Gas sensor with protected gate, sensor formation and detection |
| SE9903617D0 (en) * | 1999-10-05 | 1999-10-05 | Se Interengineering Ab | Device and method for determining the status of a product |
| US6411567B1 (en) | 2000-07-07 | 2002-06-25 | Mark A. Niemiec | Drug delivery management system |
| DE10061299A1 (en) | 2000-12-08 | 2002-06-27 | Siemens Ag | Device for determining and / or forwarding at least one environmental influence, production method and use thereof |
| JP2005500655A (en) | 2001-08-20 | 2005-01-06 | ハネウェル・インターナショナル・インコーポレーテッド | Snap action thermal switch |
| US6724195B2 (en) | 2002-03-29 | 2004-04-20 | Jerome R. Lurtz | Contact sensor |
| JP2004219080A (en) | 2003-01-09 | 2004-08-05 | Denso Corp | Semiconductor sensor and its manufacturing method |
| FI113895B (en) * | 2003-02-27 | 2004-06-30 | Metso Corp | Electrical and/or optical temperature detector/indicator for monitoring storage temperature of product packages, comprises conductive polymer layer incorporated into or onto substrate, and dedoping or doping layers |
| US7551058B1 (en) * | 2003-12-10 | 2009-06-23 | Advanced Design Consulting Usa, Inc. | Sensor for monitoring environmental parameters in concrete |
| US8052932B2 (en) | 2006-12-22 | 2011-11-08 | Research Triangle Institute | Polymer nanofiber-based electronic nose |
| WO2006048412A1 (en) * | 2004-11-08 | 2006-05-11 | Freshpoint Holdings Sa | Time-temperature indicating device |
| JP4419886B2 (en) * | 2005-03-23 | 2010-02-24 | 富士ゼロックス株式会社 | Photosensor, detected object detection device, and image forming apparatus incorporating this photosensor |
| JP4437103B2 (en) | 2005-04-22 | 2010-03-24 | 本田技研工業株式会社 | Vehicle start control method |
| CN100593214C (en) | 2005-05-27 | 2010-03-03 | 中国科学院物理研究所 | Perovskite oxide thin-film compound device |
| WO2007004948A1 (en) | 2005-06-30 | 2007-01-11 | Astrazeneca Ab | Environmental detector |
| US20080063027A1 (en) | 2006-03-15 | 2008-03-13 | Giovanni Galli | Precision temperature sensor |
| US20090085031A1 (en) * | 2006-03-16 | 2009-04-02 | Tokyo Electron Limited | Wafer-Shaped Measuring Apparatus and Method for Manufacturing the Same |
| US20100134286A1 (en) * | 2008-12-01 | 2010-06-03 | General Electric Company | Radio frequency based sensors employing analyte recognition element |
| US20080138926A1 (en) | 2006-12-11 | 2008-06-12 | Lavine James P | Two epitaxial layers to reduce crosstalk in an image sensor |
| US7997791B2 (en) * | 2007-07-24 | 2011-08-16 | Qimonda Ag | Temperature sensor, integrated circuit, memory module, and method of collecting temperature treatment data |
| KR20100081326A (en) | 2007-10-09 | 2010-07-14 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | Multifunctional potentiometric gas sensor array with an integrated temperature control and temperature sensors |
| JP5056398B2 (en) | 2007-12-19 | 2012-10-24 | 株式会社豊田中央研究所 | Method of using sensor and sensor device |
| WO2010008874A1 (en) * | 2008-06-24 | 2010-01-21 | Georgia Tech Research Corporation | Passive environmental sensing |
| KR20120081093A (en) | 2009-09-16 | 2012-07-18 | 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 | Liquid organic semiconductor material |
| EP2505978B1 (en) | 2011-03-28 | 2017-05-10 | Nxp B.V. | Temperature sensor, electronic device and temperature measurement method |
-
2012
- 2012-12-20 HK HK14112016.9A patent/HK1198555A1/en unknown
- 2012-12-20 WO PCT/EP2012/076318 patent/WO2013092823A1/en not_active Ceased
- 2012-12-20 AU AU2012357007A patent/AU2012357007B2/en not_active Ceased
- 2012-12-20 CN CN201810020939.2A patent/CN108332881A/en active Pending
- 2012-12-20 JP JP2014548003A patent/JP6262663B2/en not_active Expired - Fee Related
- 2012-12-20 IN IN4012CHN2014 patent/IN2014CN04012A/en unknown
- 2012-12-20 US US14/367,828 patent/US10215786B2/en not_active Expired - Fee Related
- 2012-12-20 EP EP12812240.5A patent/EP2795303A1/en not_active Withdrawn
- 2012-12-20 AR ARP120104856 patent/AR089357A1/en not_active Application Discontinuation
- 2012-12-20 KR KR20147019340A patent/KR20140107430A/en not_active Withdrawn
- 2012-12-20 CN CN201280063878.9A patent/CN104105960B/en not_active Expired - Fee Related
- 2012-12-20 BR BR112014014498A patent/BR112014014498A2/en not_active IP Right Cessation
- 2012-12-20 MX MX2014007676A patent/MX337266B/en active IP Right Grant
- 2012-12-20 RU RU2014130281A patent/RU2615795C2/en not_active IP Right Cessation
- 2012-12-21 TW TW101148897A patent/TWI599772B/en not_active IP Right Cessation
-
2014
- 2014-05-19 IL IL232691A patent/IL232691A0/en unknown
-
2017
- 2017-12-12 JP JP2017237471A patent/JP2018066750A/en not_active Ceased
-
2018
- 2018-12-20 US US16/228,128 patent/US20190120886A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US10215786B2 (en) | 2019-02-26 |
| WO2013092823A1 (en) | 2013-06-27 |
| JP2018066750A (en) | 2018-04-26 |
| BR112014014498A8 (en) | 2017-06-13 |
| US20150108964A1 (en) | 2015-04-23 |
| JP6262663B2 (en) | 2018-01-17 |
| CN104105960B (en) | 2018-01-12 |
| EP2795303A1 (en) | 2014-10-29 |
| IL232691A0 (en) | 2014-07-31 |
| AU2012357007B2 (en) | 2015-08-13 |
| KR20140107430A (en) | 2014-09-04 |
| IN2014CN04012A (en) | 2015-10-23 |
| AU2012357007A1 (en) | 2014-06-19 |
| CN104105960A (en) | 2014-10-15 |
| RU2615795C2 (en) | 2017-04-11 |
| RU2014130281A (en) | 2016-02-20 |
| BR112014014498A2 (en) | 2017-06-13 |
| CN108332881A (en) | 2018-07-27 |
| TWI599772B (en) | 2017-09-21 |
| TW201341789A (en) | 2013-10-16 |
| MX2014007676A (en) | 2014-11-10 |
| HK1198555A1 (en) | 2015-05-15 |
| MX337266B (en) | 2016-02-22 |
| JP2015502549A (en) | 2015-01-22 |
| AR089357A1 (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190120886A1 (en) | Sensor arrangement for a packaging of a medicament | |
| US12332104B2 (en) | Sensor, cartridge and drug delivery device | |
| JP6942114B2 (en) | Sensors, cartridges, and drug delivery devices | |
| JP6862417B2 (en) | Sensors, cartridges, and drug delivery devices | |
| JP6901398B2 (en) | Injection device sensor device | |
| DK2911723T3 (en) | PHARMACEUTICAL ADMINISTRATION DEVICE WITH PHARMACEUTICAL CONTAINER INCLUDING A SENSOR AND OPTICAL DATA TRANSMISSION SYSTEM | |
| JP6873971B2 (en) | Sensors for drug delivery devices | |
| US20160015901A1 (en) | Bearing Component for a Piston Rod of a Drug Delivery Device, Piston Rod Comprising the Bearing Component, and Drug Delivery Device | |
| US9861766B2 (en) | Medicament delivery device with needle alignment detection mechanism | |
| US10436619B2 (en) | Flow rate sensor | |
| HK1239804B (en) | Drug delivery device with flow rate sensor | |
| HK1239804A1 (en) | Drug delivery device with flow rate sensor | |
| HK1209659B (en) | Drug delivery device with drug container comprising a sensor and optical data transmission system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIETZMANN, HARDY;GROESCHKE, JASMIN;JUHNKE, HANNO;AND OTHERS;SIGNING DATES FROM 20130118 TO 20130125;REEL/FRAME:047844/0810 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |